No Data
Jilin Aodong Pharmaceutical Group (000623.SZ): The holding subsidiary has received the notification of compliance inspection for Pharmaceutical GMP.
On February 10, Gelonghui reported that Jilin Aodong Pharmaceutical Group (000623.SZ) announced that its holding subsidiary, Jilin Aodong Yanbian Pharmaceutical Co., Ltd., received the "Pharmaceutical GMP Compliance Inspection Notification" approved and issued by the Jilin Provincial Drug Administration. This successful passing of the Pharmaceutical GMP compliance inspection by Yanbian Pharmaceutical indicates that the mentioned production scope meets the requirements of the "Good Manufacturing Practice for Pharmaceutical Production."
Jilin Aodong Pharmaceutical Group (000623.SZ): has cumulatively repurchased 1.71% of its shares.
On February 5, Glonghui reported that Jilin Aodong Pharmaceutical Group (000623.SZ) announced that as of January 31, 2025, the company had cumulatively repurchased 20,443,900 shares of its stock through a dedicated securities account via centralized bidding Trade, accounting for 1.71% of the total share capital of 1,195,895,387 shares as of January 31, 2025. The highest Fill Price was 19.21 yuan per share, the lowest Fill Price was 15.80 yuan per share, and the total amount paid was 0.369 billion yuan (excluding transaction fees).
Jilin Aodong Pharmaceutical Group (000623.SZ): Amlodipine Atorvastatin Calcium Tablets have obtained approval for the pharmaceutical supplementary application.
Jilin Aodong Pharmaceutical Group (000623.SZ) announced that recently, the company's holding subsidiary Jilin Aodong Pharmaceutical Group Yanji Branch...
Many Still Looking Away From Jilin Aodong Pharmaceutical Group Co., Ltd. (SZSE:000623)
Jilin Aodong Pharmaceutical Group (000623.SZ): Taonan Pharmaceutical has obtained the registration certificate for Lenvatinib Mesylate capsules.
On January 13, Gelonghui reported that Jilin Aodong Pharmaceutical Group (000623.SZ) announced that recently, its controlling subsidiary, Jilin Aodong Taonan Pharmaceutical Co., Ltd. (referred to as "Taonan Pharmaceutical"), received two "Drug Registration Certificates" from the National Medical Products Administration for Lenvatinib Mesylate Capsules with specifications of 10 mg and 4 mg. Lenvatinib Mesylate Capsules are indicated for: 1. Patients with unresectable hepatocellular carcinoma who have not received any systemic treatment before. The key research on Lenvatinib Mesylate excluded patients with hepatocellular carcinoma who could receive acceptable local therapy, and there is currently no available research data for these patients.
Jilin Aodong Pharmaceutical Group (000623.SZ): The scope of business covers Chinese Patent Medicine, Traditional Chinese Medicine granules, Traditional Chinese Medicine pieces, Chemical Drug, and so on.
On January 9, Gelonghui reported that Jilin Aodong Pharmaceutical Group (000623.SZ) stated on the investor interaction platform that its industry is the Pharmaceutical Manufacturing Industry, primarily engaged in research and development, manufacturing, and sales of Traditional Chinese Medicine and Chemical Drug. Currently, the company's business scope includes Chinese Patent Medicine, Traditional Chinese Medicine prescription granules, Traditional Chinese Medicine slices, Chemical Drug, etc., while actively expanding into health food, food, breeding, planting, and other fields, gradually forming a "pharmaceutical + finance + big health" multi-driven development model. With the continued promotion of the ice and snow economy by the state, the Northeast ice and snow tourism is booming, and the company will make full use of the popular ice and snow tourism to enhance product marketing and increase promotion efforts.